Table 3 Subgroup analyses of the risk of Alzheimer’s disease among control, psoriasis patients treated with or without systemic therapy according to sex, age, presence or absence of diabetes mellitus, hypertension and dyslipidemia.
Subgroup | Â | Event(n) | Incidence rate (per 1000 person-years) | HR (95%CI) | |
|---|---|---|---|---|---|
Model 3 | P for interaction | ||||
Male | Control | 21,680 | 4.472 | 1 (Ref.) | 0.1987 |
Psoriasis group | 4,913 | 5.077 | 1.103 (1.069, 1.137) | ||
No systemic therapy | 4,718 | 5.234 | 1.112 (1.077, 1.147) | ||
Systemic therapy | 195 | 2.939 | 0.922 (0.798, 1.058) | ||
Female | Control | 28,529 | 6.889 | 1 (Ref.) | |
Psoriasis group | 6,398 | 7.747 | 1.087 (1.058, 1.117) | ||
No systemic therapy | 6,171 | 7.931 | 1.088 (1.059, 1.119) | ||
Systemic therapy | 227 | 4.753 | 1.056 (0.924, 1.2) | ||
40 y < Age < 65 y | Control | 4,852 | 0.743 | 1 (Ref.) | <0.0001 |
Psoriasis group | 1,333 | 1.022 | 1.303 (1.226, 1.385) | ||
No systemic therapy | 1,265 | 1.044 | 1.32 (1.24, 1.404) | ||
Systemic therapy | 68 | 0.739 | 1.056 (0.823, 1.33) | ||
Age > 65 y | Control | 45,357 | 18.430 | 1 (Ref.) | |
Psoriasis group | 9,978 | 20.386 | 1.082 (1.058, 1.105) | ||
No systemic therapy | 9,624 | 20.592 | 1.085 (1.062, 1.109) | ||
Systemic therapy | 354 | 16.038 | 0.99 (0.89, 1.097) | ||
No DM | Control | 39,661 | 4.899 | 1 (Ref.) | 0.8578 |
Psoriasis group | 8,386 | 5.377 | 1.093 (1.067, 1.119) | ||
No systemic therapy | 8,082 | 5.538 | 1.097 (1.071, 1.124) | ||
Systemic therapy | 304 | 3.035 | 0.983 (0.877, 1.099) | ||
DM | Control | 10,548 | 11.794 | 1 (Ref.) | |
Psoriasis group | 2,925 | 12.491 | 1.09 (1.046, 1.135) | ||
No systemic therapy | 2,807 | 12.746 | 1.094 (1.05, 1.141) | ||
Systemic therapy | 118 | 8.462 | 0.994 (0.824, 1.185) | ||
No HTN | Control | 24,495 | 3.716 | 1 (Ref.) | 0.0043 |
Psoriasis group | 4,989 | 4.041 | 1.127 (1.093, 1.161) | ||
No systemic therapy | 4,790 | 4.162 | 1.133 (1.099, 1.169) | ||
Systemic therapy | 199 | 2.380 | 0.982 (0.852, 1.126) | ||
HTN | Control | 25,714 | 10.724 | 1 (Ref.) | |
Psoriasis group | 6,322 | 11.307 | 1.069 (1.04, 1.099) | ||
No systemic therapy | 6,099 | 11.538 | 1.073 (1.043, 1.103) | ||
Systemic therapy | 223 | 7.310 | 0.984 (0.86, 1.119) | ||
No dyslipidemia | Control | 39,940 | 5.150 | 1 (Ref.) | 0.1967 |
Psoriasis group | 8,340 | 5.669 | 1.078 (1.053, 1.104) | ||
No systemic therapy | 8,031 | 5.836 | 1.083 (1.057, 1.109) | ||
Systemic therapy | 309 | 3.254 | 0.976 (0.871, 1.09) | ||
Dyslipidemia | Control | 10,269 | 8.325 | 1 (Ref.) | |
Psoriasis group | 2,971 | 9.213 | 1.13 (1.084, 1.177) | ||
No systemic therapy | 2,858 | 9.422 | 1.135 (1.088, 1.183) | ||
Systemic therapy | 113 | 5.897 | 1.02 (0.843, 1.222) | ||
